8-K: Avantor Appoints Dame Louise Makin to Board of Directors

Avantor, Inc. has appointed Dame Louise Makin as an independent director to its Board, effective November 4, 2024.

Summary

• Avantor, Inc. has elected Dame Louise Makin to its Board of Directors as an independent director.
• Her term will expire at the 2025 Annual Meeting of Stockholders.
• Dame Louise fills a vacant board seat.
• She currently serves as the non-executive chair of Halma plc.
• She previously served as CEO of BTG plc, leading its transformation and acquisition by Boston Scientific.
• She has held leadership positions at Baxter Healthcare and served on several other boards.
• The board has determined that she meets all independence requirements.
• She will receive an annual cash retainer of $95,000, prorated for 2024, and a grant of restricted stock units valued at $210,000, also prorated for 2024.
• The restricted stock units will vest in one year, subject to continued service.
• She will also receive a $15,000 annual stipend for U.S. income tax planning and returns preparation services.

Sentiment

Score: 7

Explanation: The document reflects a positive development with the appointment of an experienced director, but it is a routine corporate event and does not indicate any significant change in the company's financial outlook.

Positives

• Dame Louise Makin brings extensive experience in the life sciences and healthcare industries.
• Her leadership experience at BTG plc, including its acquisition by Boston Scientific, is a significant asset.
• Her appointment fills a vacant board seat, strengthening the board's composition.
• Her independence ensures objective oversight and governance.

Risks

• There are no immediate risks identified in the document.
• The document does not mention any potential risks associated with the appointment.

Future Outlook

The document does not contain any specific forward-looking statements beyond the appointment of the new director.

Management Comments

• The Board of Directors elected Dame Louise Makin upon the recommendation of its Nominating and Governance Committee.
• The Board has determined that Dame Louise meets all applicable requirements to serve on the Board.

Industry Context

The appointment of Dame Louise Makin, with her extensive experience in the life sciences and healthcare sectors, aligns with Avantor's focus on these industries. Her background in leading a company through a major acquisition is also relevant to Avantor's growth strategy.

Comparison to Industry Standards

• The compensation package for Dame Louise Makin, including the annual retainer and stock grants, is consistent with standard practices for non-executive directors of publicly traded companies on the New York Stock Exchange.
• Her experience as a non-executive director on other boards such as Intertek Group plc, Theramex Group, Woodford Patient Capital Trust plc and Atotech Ltd is comparable to other board members in similar companies.
• Her previous role as CEO of BTG plc and her leadership positions at Baxter Healthcare are similar to the backgrounds of other board members in the life sciences and healthcare industries.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced director positively.
• The appointment is not expected to have a direct impact on employees, customers, suppliers, or creditors.

Next Steps

• Dame Louise Makin will begin her term on the Board of Directors.
• Her restricted stock units will vest in one year, subject to continued service.
• She will participate in the 2025 Annual Meeting of Stockholders.

Key Dates

Keywords

Board of Directors, Independent Director, Corporate Governance, Executive Appointment, Life Sciences, Healthcare, BTG plc, Halma plc, Avantor